MaxCyte (NASDAQ:MXCT - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results after the market closes on Wednesday, May 7th. Analysts expect MaxCyte to post earnings of ($0.10) per share and revenue of $9.05 million for the quarter.
MaxCyte Stock Down 3.7 %
Shares of MXCT stock traded down $0.11 during trading hours on Monday, reaching $2.72. The company's stock had a trading volume of 74,633 shares, compared to its average volume of 532,343. MaxCyte has a fifty-two week low of $2.21 and a fifty-two week high of $5.26. The company has a market capitalization of $288.64 million, a price-to-earnings ratio of -7.99 and a beta of 1.39. The firm's 50 day simple moving average is $2.92 and its 200-day simple moving average is $3.66.
Wall Street Analyst Weigh In
MXCT has been the subject of several research analyst reports. Stifel Nicolaus lowered their target price on MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, March 12th. BTIG Research set a $6.00 price objective on shares of MaxCyte and gave the stock a "buy" rating in a research report on Wednesday, March 12th.
Get Our Latest Analysis on MXCT
MaxCyte Company Profile
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Further Reading
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
